ABSTRACT
Background Long-term anticoagulation (AC) therapy reduces the risk of stroke in patients with Atrial Fibrillation (AF). Data on the impact of AC on in-hospital stroke outcomes is lacking.
Methods The National Inpatient Sample was used to identify adult inpatients with AF and a primary diagnosis of ischemic stroke between 2016 and 2020. Data was stratified between patients on AC users and nonusers. A multivariate regression model was used to describe the in-hospital outcomes, adjusting for significant comorbidities.
Results A total of 655,540 patients with AF and a diagnosis of ischemic stroke were included, of which 194,560 (29.7%) were on long-term AC. Patients on AC tended to be younger (mean age, 77 vs 78), had a higher average CHA2DS2VASc score (4.48 vs 4.20), higher rates of hypertension (91% vs 88%), hyperlipidemia (64% vs 59%), and heart failure (34% vs 30%) compared to patients not on long-term AC. Use of AC was associated with decreased in-hospital mortality (aOR [95% CI]: 0.62 [0.60 - 0.63]), decreased stroke severity (mean NIHSS, 8 vs 10), decreased use of tPA (aOR 0.42 [0.41 - 0.43]), mechanical thrombectomy (aOR 0.85 [0.83 - 0.87]), hemorrhagic conversion (aOR 0.69 [0.67 - 0.70]), gastrointestinal bleeding (aOR 0.74 [0.70 - 0.77]), and discharge to skilled nursing facilities (aOR 0.90 [0.89 - 0.91]), compared to patients not on AC (P<0.001 for all comparisons).
Conclusion Among patients with AF admitted with acute ischemic stroke, AC use prior to stroke was associated with decreased in-hospital mortality, decreased stroke severity, decreased discharge to SNF, and fewer stroke-related and bleeding complications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was exempted from institutional review board approval due to the use of a deidentified administrative database
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Authors declare no conflict of interest.
Data Availability
The National Inpatient Sample is publicly available for purchase through the Agency of Healthcare Research and Quality. The ICD10 codes used in this study are available in the Supplementary Materials.
Abbreviations
- AF
- Atrial Fibrillation
- NVAF
- Nonvalvular Atrial Fibrillation
- AC
- Anticoagulation
- DOAC
- direct oral anticoagulants
- VKA
- vitamin K antagonists
- LAAC
- Left Atrial Appendage Closure
- IS
- Ischemic Stroke
- SEE
- Systemic Embolic Events
- TIA
- Transient Ischemic Attack
- NIS
- National Inpatient Sample
